JOURNAL OF PHARMA INSIGHTS AND RESEARCH

REVIEW ARTICLE

A Comprehensive Approach to the Management of Severe Coronary Artery Calcification Using Coronary Atherectomy

Suraj Agrahari*[1], Shubham Garg[2], Aamir Hussain war[1], Abhishek Kumar[1], Mussadiq Hussain Tantray[1], Rajat Koundal[3], Hurmandeep Kaur[2]

[1]*UG Scholar, College of Pharmacy, B Pharmacy, RIMT University, Mandi Gobindgarh, Punjab, India*
[2]*Assistant Professor, College of Pharmacy, RIMT University, Mandi Gobindgarh, Punjab, India*
[3]*Associate Professor, College of Pharmacy, RIMT University, Mandi Gobindgarh, Punjab, India.*

Publication history**:** Received on 28th March; Revised on 3rd April; Accepted on 10th April

Article DOI: 10.5281/zenodo.11200077

Abstract: Coronary atherosclerosis involves the buildup of plaques in the arteries supplying blood to the heart muscle, leading to conditions like angina and heart attack. Coronary atherectomy, a minimally invasive procedure, aims to modify or remove atherosclerotic plaque, restoring proper blood flow. Various atherectomy techniques (orbital, directional, rotational, laser) use specific instruments to cut, shave, or vaporize plaque, depending on lesion characteristics and patient status. Benefits include improved stent delivery, expansion, and apposition in severely calcified lesions, potentially reducing ischemic complications. The etiology of coronary atherosclerosis is multifactorial, involving lipid accumulation, inflammation, endothelial dysfunction, and vascular remodeling. Diagnosis employs imaging (invasive coronary angiography, CT coronary angiography), analysis of genetic and protein markers (APOE, PCSK9, hs-CRP), and trace element assessment. Understanding atherogenesis mechanisms is crucial for effective prevention and management. The review discusses atherectomy modalities, procedural considerations, clinical implications, disease pathophysiology, and diagnostic approaches.

Keywords: Coronary atherectomy; Coronary calcification; Percutaneous intervention; Atherosclerosis; Angiography; Angina.

1. Introduction

Coronary artery disease (CAD), characterized by the buildup of atherosclerotic plaques within the arteries supplying oxygenated blood to the heart muscle, remains a leading cause of morbidity and mortality globally. Despite significant advancements in preventive strategies and treatment modalities, the burden of CAD continues to escalate, underscoring the need for innovative and effective interventions. [1, 2] Atherosclerosis, the underlying pathological process, is a complex and multifaceted condition involving various cellular and molecular mechanisms. The accumulation of lipids, particularly low-density lipoprotein (LDL) cholesterol, within the arterial wall initiates an inflammatory response, leading to the recruitment and activation of immune cells, such as macrophages and lymphocytes. [3] This inflammatory milieu promotes the formation of atherosclerotic plaques, which can progressively narrow the lumen of the coronary arteries, impeding blood flow and increasing the risk of ischemic events, including angina and myocardial infarction. [4,5]

Severe coronary artery calcification (CAC), a common manifestation of advanced atherosclerosis, poses significant challenges in the management of CAD, particularly during percutaneous coronary interventions (PCI).[6,7] Calcified plaques are notoriously resistant to conventional balloon angioplasty and stent implantation, often resulting in suboptimal stent expansion, malapposition, and an increased risk of procedural complications, such as dissection, perforation, and restenosis. [8] In recent years, coronary atherectomy has emerged as a promising technique for addressing the challenges posed by severe CAC. Atherectomy, a minimally invasive procedure, involves the selective removal or modification of calcified plaque within the coronary arteries, facilitating improved stent delivery, expansion, and apposition. Various atherectomy modalities have been developed, including orbital, directional, rotational, and laser atherectomy, each employing unique mechanisms and instruments to address specific lesion characteristics and patient needs. [9, 10] Beyond its procedural benefits, coronary atherectomy has the potential to improve long-term clinical outcomes by reducing the risk of ischemic complications and enhancing the overall success of PCI in patients with severe CAC. However, the widespread adoption of atherectomy techniques has been hindered by concerns regarding procedural complexity, potential complications, and limited evidence from large-scale clinical trials. [11]

---

* Corresponding author: Suraj Agrahari

Parallel to the advancements in interventional techniques, our understanding of the etiology and pathophysiology of coronary atherosclerosis has evolved significantly. The interplay between genetic, environmental, and lifestyle factors in the development and progression of atherosclerosis has been extensively studied, paving the way for the identification of novel diagnostic and therapeutic targets. [12] Diagnostic approaches for coronary atherosclerosis have also witnessed remarkable progress, encompassing imaging modalities (invasive coronary angiography, computed tomography coronary angiography), genetic and protein markers (APOE, PCSK9, hs-CRP), and the assessment of trace elements. [13] These diagnostic tools not only aid in risk stratification but also hold the potential for personalized and targeted interventions, further enhancing the management of CAD. The objective of this work is to provide a comprehensive review of coronary atherectomy techniques, their clinical implications, and the current understanding of the etiology, pathophysiology, and diagnostic approaches in coronary atherosclerosis.

2. Etiology and Pathophysiology of Coronary Atherosclerosis

Coronary atherosclerosis is a complex and multifactorial disease process that involves the interplay of various genetic, environmental, and lifestyle factors. Understanding the etiology and pathophysiology of this condition is crucial for developing effective preventive and therapeutic strategies. [14, 15] The pathogenesis of coronary atherosclerosis is initiated by the accumulation of low-density lipoprotein (LDL) cholesterol within the arterial wall, a process known as lipid insudation. This lipid accumulation triggers an inflammatory response, leading to the recruitment of monocytes and their differentiation into macrophages. These macrophages then ingest the oxidized LDL particles, transforming into foam cells, which are the hallmark of early atherosclerotic lesions, known as fatty streaks. Endothelial dysfunction, characterized by impaired endothelium-dependent vasodilation and increased expression of adhesion molecules, plays a pivotal role in the progression of atherosclerosis. [16] This dysfunction facilitates the adhesion and transmigration of inflammatory cells, such as monocytes and T-lymphocytes, into the arterial intima, further propagating the inflammatory response. As the disease progresses, smooth muscle cells migrate from the medial layer of the artery into the intima, where they proliferate and produce extracellular matrix components, including collagen and elastin. This process leads to the formation of a fibrous cap that covers the lipid-rich necrotic core of the atherosclerotic plaque. [17, 18]

The stability of the atherosclerotic plaque is determined by the balance between the fibrous cap and the necrotic core. Plaques with a thin, fibrous cap and a large, lipid-rich necrotic core are considered vulnerable and prone to rupture. Plaque rupture exposes the highly thrombogenic contents of the necrotic core to the bloodstream, triggering platelet activation and thrombus formation, which can lead to acute coronary syndromes, such as unstable angina, myocardial infarction, and sudden cardiac death. [19] The etiology of coronary atherosclerosis is multifactorial, with various risk factors contributing to its development and progression. These risk factors can be broadly classified into non-modifiable and modifiable factors.

Non-modifiable risk factors include:
- Age
- Gender
- Family history and genetic predisposition

Modifiable risk factors include:
- Dyslipidemia (elevated LDL cholesterol, low HDL cholesterol, and high triglycerides)
- Hypertension
- Diabetes mellitus
- Obesity and sedentary lifestyle
- Smoking
- Unhealthy diet
- Chronic inflammation

The interplay between these risk factors and their impact on the pathophysiological processes involved in atherosclerosis can vary among individuals, contributing to the heterogeneity of the disease manifestations. Furthermore, recent research has shed light on the role of epigenetic modifications, such as DNA methylation and histone modifications, in the development and progression of coronary atherosclerosis. [20, 21]] These epigenetic changes can influence gene expression patterns and cellular processes involved in the pathogenesis of the disease, providing new insights into potential therapeutic targets. Understanding the etiology and pathophysiology of coronary atherosclerosis is essential for developing personalized and targeted interventions. [22] By identifying and addressing the modifiable risk factors and leveraging our knowledge of the underlying molecular mechanisms, we can potentially slow or even reverse the progression of this debilitating condition, ultimately improving patient outcomes and reducing the burden of cardiovascular disease.

3. Diagnostic Approaches for Coronary Atherosclerosis

The accurate diagnosis and assessment of coronary atherosclerosis are crucial for determining appropriate treatment strategies and minimizing the risk of adverse cardiovascular events. Several diagnostic approaches have been developed, including imaging modalities, genetic and protein markers, and the analysis of trace elements. [23] These approaches provide valuable insights into the presence, extent, and progression of coronary atherosclerosis, enabling personalized management and risk stratification. [24, 25]

3.1. Imaging Modalities

Imaging techniques play a pivotal role in the diagnosis and evaluation of coronary atherosclerosis. These modalities not only visualize the anatomical changes in the coronary arteries but also provide functional and physiological information about the cardiovascular system. [26]

3.1.1. Invasive Coronary Angiography (ICA)

Considered the gold standard for assessing coronary artery disease, ICA involves the injection of contrast dye into the coronary arteries, allowing for the visualization of luminal narrowing and stenosis. [27] While ICA provides excellent spatial resolution and anatomical detail, it is an invasive procedure with associated risks and limitations in detecting non-obstructive plaque.

3.1.2. Computed Tomography Coronary Angiography (CTCA)

CTCA is a non-invasive imaging technique that uses advanced CT technology to visualize the coronary arteries and detect the presence and extent of calcified and non-calcified plaque. It offers high diagnostic accuracy and can assess plaque characteristics, such as composition and degree of stenosis. CTCA is particularly useful for ruling out significant coronary artery disease in patients with low to intermediate risk. [28]

3.1.3. Intravascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT)

IVUS and OCT are invasive imaging modalities that provide detailed cross-sectional views of the coronary arteries and plaque morphology. IVUS uses high-frequency sound waves, while OCT employs near-infrared light to generate high-resolution images of the vessel wall. These techniques are valuable for assessing plaque composition, degree of stenosis, and guiding interventional procedures. [29]

3.1.4. Cardiac Magnetic Resonance Imaging (CMR)

CMR is a non-invasive modality that offers excellent soft tissue contrast and functional assessment of the heart. It can detect and characterize atherosclerotic plaque, evaluate myocardial viability, and assess cardiac function and perfusion. CMR is particularly useful in patients with contraindications to other imaging techniques or complex coronary anatomy. [30]

Table 1. Comparison of Coronary Atherectomy Techniques

Technique	Mechanism of Action	Advantages	Limitations
Orbital Atherectomy (OA)	Utilizes an eccentrically mounted diamond-coated crown to selectively ablate calcified plaque by creating microscopic fractures (differential sanding).	Can treat severely stenotic calcified lesions at low speeds; treats large diameter arteries at high speeds; minimizes trauma to non-calcified vessel wall.	Limited ability to modify non-calcified plaque; risk of dissection or perforation if not used properly.
Directional Atherectomy (DA)	Uses a specialized catheter with a cutting window and a cutter assembly to shave off plaque, which is collected within the catheter's nosecone.	Useful for eccentric or ostial lesions; can be used in both coronary and peripheral arteries.	Procedural complexity; risk of distal embolization; limited ability to treat diffuse or heavily calcified lesions.
Rotational Atherectomy (RA)	Employs a high-speed rotating burr to ablate calcified plaque, creating microscopic particles that are dispersed distally.	Effective in treating heavily calcified lesions; long-standing experience with the technique.	Higher risk of slow or no-reflow, dissection, and perforation; limited ability to treat large diameter vessels.
Laser Atherectomy	Uses high-energy laser beams to vaporize or ablate atherosclerotic plaque.	Can target specific plaque compositions based on different wavelengths.	Risk of vessel wall damage, dissection, or perforation; limited availability and experience with the technique.

3.2. Genetic and Protein Markers

Advances in molecular biology and genetics have led to the identification of various genetic and protein markers associated with the development and progression of coronary atherosclerosis. [31] These markers provide valuable insights into the underlying pathophysiological mechanisms and can aid in risk stratification and targeted therapeutic interventions.

3.2.1. Genetic Markers

Several genetic variants have been linked to an increased risk of coronary atherosclerosis, including mutations in the APOE, PCSK9, and IL-6 genes. These genetic markers are involved in lipid metabolism, inflammation, and vascular function, and their identification can help identify individuals at higher risk and guide personalized treatment strategies. [32]

3.2.2. Protein Markers

Specific proteins, such as high-sensitivity C-reactive protein (hs-CRP), lipoprotein(a) [Lp(a)], and adiponectin, have been associated with the development and progression of coronary atherosclerosis. [33] Elevated levels of hs-CRP and Lp(a) are indicative of systemic inflammation and increased risk of plaque formation and thrombosis, respectively. In contrast, low levels of adiponectin, an adipokine with anti-atherogenic and anti-inflammatory properties, are linked to an increased risk of atherosclerosis. [34]

3.2.3. Trace Elements

Trace elements, which are essential minerals required in minute quantities for various physiological functions, have been implicated in the pathogenesis of cardiovascular diseases, including coronary atherosclerosis. [35] The assessment of trace element levels can provide insights into the disease process and potential therapeutic targets.

- Magnesium (Mg): Magnesium plays a crucial role in blood pressure regulation, endothelial function, and vascular tone maintenance. Low magnesium levels have been associated with an increased risk of coronary atherosclerosis and adverse cardiovascular events. [36]
- Selenium (Se): Selenium is an essential antioxidant that protects cells from oxidative damage and may influence endothelial function and inflammatory processes. Both deficiency and excess levels of selenium have been linked to an increased risk of coronary atherosclerosis. [37]
- Zinc (Zn): Zinc is involved in wound healing, immune function, and antioxidant defense mechanisms. Imbalances in zinc levels can affect endothelial function and vascular homeostasis, potentially contributing to the development of coronary atherosclerosis. [38]
- Copper (Cu): Copper acts as a cofactor for various enzymes involved in lipid metabolism, collagen formation, and antioxidant defense. Dysregulation of copper levels has been associated with increased oxidative stress and the progression of atherosclerosis. [39]

The integration of these diagnostic approaches, including imaging modalities, genetic and protein markers, and trace element analysis, provides a comprehensive evaluation of coronary atherosclerosis. [40] By combining these techniques, clinicians can obtain a multifaceted understanding of the disease process, enabling accurate risk stratification, personalized treatment strategies, and targeted interventions to prevent or slow the progression of coronary atherosclerosis. [41] It is important to note that the choice of diagnostic approach should be tailored to each individual patient, considering factors such as risk profile, clinical presentation, and the availability of resources. Additionally, ongoing research continues to explore novel biomarkers and advanced imaging techniques, further refining our ability to diagnose and manage coronary atherosclerosis effectively. [42]

Table 2. Genetic and Protein Markers in Coronary Atherosclerosis

Marker	Description	Role in Atherosclerosis
APOE Gene	Variations in the apolipoprotein E (APOE) gene, particularly the ε2, ε3, and ε4 alleles.	Involved in lipid metabolism and cholesterol transport, influencing the risk of atherosclerosis.
PCSK9 Gene	Mutations affecting proprotein convertase subtilisin/kexin type 9 (PCSK9).	Regulates LDL receptor activity, affecting LDL cholesterol levels and the risk of atherosclerosis.
IL-6 Gene	Polymorphisms in the interleukin-6 (IL-6) gene.	Modulates the inflammatory response linked to atherosclerosis.
High-Sensitivity C-Reactive Protein (hs-CRP)	Elevated levels of hs-CRP, an inflammatory marker.	Predictor of atherosclerosis progression and systemic inflammation.
Lipoprotein(a) [Lp(a)]	Increased levels of Lp(a), a lipoprotein particle.	Promotes thrombosis and plaque formation, increasing the risk of atherosclerosis.

Adiponectin	Decreased levels of adiponectin, an adipokine with anti-atherogenic and anti-inflammatory properties.	Linked to obesity, insulin resistance, and a higher risk of atherosclerosis.

3.3. Coronary Atherectomy Techniques

Coronary atherectomy encompasses a range of minimally invasive techniques aimed at modifying or removing calcified plaque within the coronary arteries, thereby facilitating improved stent delivery, expansion, and apposition. [43] These techniques have evolved significantly over the years, offering interventional cardiologists a diverse array of tools to address the challenges posed by severe coronary artery calcification (CAC). [44]

3.3.1. Orbital Atherectomy (OA)

Orbital atherectomy is a relatively new technique that utilizes an eccentrically mounted diamond-coated crown to selectively ablate calcified plaque. The crown rotates at high speeds (up to 120,000 rpm) while advanced over a guidewire, creating microscopic fractures within the calcified lesion [45]. This process, known as differential sanding, preferentially modifies the calcified plaque while minimizing trauma to the non-calcified vessel wall. [46] OA has been shown to be effective in treating severely calcified lesions, improving stent delivery, expansion, and apposition.

3.3.2. Directional Atherectomy (DA)

Directional atherectomy employs a specialized catheter with a cutting window and a cutter assembly. The cutter, driven by a turbine or an air-powered mechanism, protrudes through the cutting window and shaves off the plaque as the catheter is advanced. [47] The excised plaque is then collected within the catheter's nosecone for removal. This technique is particularly useful for addressing eccentric or ostial lesions and can be used in both coronary and peripheral arteries.

3.3.3. Rotational Atherectomy (RA)

Rotational atherectomy, one of the earliest atherectomy techniques, utilizes a high-speed rotating burr (up to 200,000 rpm) mounted on a flexible shaft. The burr, available in various sizes, is advanced through a guide catheter and used to ablate calcified plaque by creating microscopic particles. These particles are then dispersed into the distal vasculature, relying on the body's ability to clear them over time. RA is particularly effective in treating heavily calcified lesions but carries a higher risk of complications, such as slow or no-reflow, dissection, and perforation. [48]

3.3.4. Laser Atherectomy

Laser atherectomy employs high-energy laser beams to vaporize or ablate atherosclerotic plaque. The laser energy is delivered through a specialized catheter system, and different wavelengths can be used to target specific plaque compositions. This technique has been utilized for both coronary and peripheral artery disease, but its use has been limited due to concerns about vessel wall damage and the potential for dissection or perforation. Each of these atherectomy techniques has its unique advantages and limitations, and the choice of technique often depends on factors such as lesion characteristics, vessel anatomy, and operator experience. [49] In some cases, a combination of atherectomy modalities may be employed to achieve optimal lesion modification and stent delivery. It is important to note that while coronary atherectomy offers potential benefits in the treatment of severe CAC, these procedures are technically demanding and carry a higher risk of complications compared to conventional percutaneous coronary interventions (PCI). Careful patient selection, meticulous procedural technique, and close monitoring are essential to ensure favorable outcomes.

4. Clinical Implications and Outcomes of Coronary Atherectomy

Coronary atherectomy has emerged as a valuable interventional technique for addressing the challenges posed by severe coronary artery calcification (CAC) during percutaneous coronary interventions (PCI). The clinical implications and outcomes of this procedure have been extensively studied, providing insights into its potential benefits and limitations. One of the primary clinical implications of coronary atherectomy is its ability to facilitate optimal stent delivery, expansion, and apposition in severely calcified lesions. [50] Conventional balloon angioplasty and stent implantation may be ineffective in these cases, leading to suboptimal stent expansion, malapposition, and an increased risk of complications such as stent thrombosis and restenosis. By modifying or removing the calcified plaque, atherectomy techniques enhance the chances of successful stent deployment and ensure proper vessel scaffolding.

Moreover, coronary atherectomy has been associated with improved procedural outcomes and reduced ischemic complications in patients with severe CAC undergoing PCI. Studies have shown that the use of atherectomy devices can lower the incidence of periprocedural myocardial infarction, slow or no-reflow phenomena, and dissection or perforation of the coronary arteries. These improved outcomes translate into better short-term and long-term clinical outcomes, including reduced rates of major adverse cardiovascular events (MACE), such as death, myocardial infarction, and target vessel revascularization. However, it is important to note that coronary atherectomy is a technically demanding procedure that requires specialized training and expertise. [51-53] The risk of complications, such as coronary artery dissection, perforation, or distal embolization, is higher compared to conventional PCI, necessitating careful patient selection and meticulous procedural technique. Additionally, the long-term outcomes of coronary atherectomy are influenced by various factors, including the underlying severity of coronary artery disease, the presence of comorbidities, and adherence to lifestyle modifications and medical therapy. [54, 55] Ongoing research and large-scale clinical trials are necessary to further evaluate the long-term efficacy and safety of different atherectomy modalities in specific patient populations.

5. Future Perspectives and Challenges

As our understanding of coronary atherosclerosis and the implications of severe CAC continues to evolve, the role of coronary atherectomy is expected to expand. However, several challenges and opportunities lie ahead, shaping the future perspectives of this interventional technique. [56-59] One area of focus is the development of newer and more advanced atherectomy devices and technologies. Ongoing research efforts are directed toward enhancing the precision, safety, and efficiency of atherectomy procedures.[60-63] This includes the exploration of novel plaque modification techniques, such as the use of ultrasound or laser-based systems, which may offer improved lesion crossing and plaque modification capabilities while minimizing the risk of complications. [64]

Furthermore, the integration of atherectomy techniques with other interventional technologies, such as intravascular imaging modalities (IVUS, OCT) and physiological assessment tools (fractional flow reserve, instantaneous wave-free ratio), holds promise for optimizing procedural outcomes. By combining these modalities, interventional cardiologists can gain a more comprehensive understanding of lesion characteristics, plaque composition, and functional significance, enabling personalized treatment strategies and improved decision-making. Another area of interest is the identification of specific patient subgroups that may benefit most from coronary atherectomy. [65] As our understanding of the genetic, molecular, and cellular mechanisms underlying coronary atherosclerosis expands, there may be opportunities to develop personalized risk stratification models and tailor atherectomy strategies based on individual patient profiles. Additionally, the role of coronary atherectomy in the management of patients with complex coronary artery disease, such as those with chronic total occlusions (CTOs) or diffuse calcified lesions, is an area of active research. Exploring the efficacy and safety of atherectomy techniques in these challenging patient populations may expand the indications and utility of these procedures. However, the widespread adoption of coronary atherectomy techniques also faces several challenges. These include the need for specialized operator training, the associated procedural costs, and the potential for complications. Addressing these challenges through education, cost-effectiveness analyses, and the development of standardized protocols and guidelines will be crucial for the successful integration of atherectomy techniques into routine clinical practice. Furthermore, the long-term comparative effectiveness of different atherectomy modalities, particularly in terms of durability, restenosis rates, and long-term clinical outcomes, requires further investigation through large-scale, randomized controlled trials.

6. Conclusion

In conclusion, coronary atherectomy represents a promising interventional approach in the management of severe coronary artery calcification. While the clinical implications and outcomes of these techniques are well-established, ongoing research and technological advancements will shape the future of coronary atherectomy, potentially expanding its role in the treatment of complex coronary artery disease and improving patient outcomes.

References

[1] Albanese I, Khan K, Barratt B, Al-Kindi H, and Schwertani A: Atherosclerotic calcification: Wnt is the hint . J Am Heart Assoc. 2018, 7:10.1161/JAHA.117.007356

[2] Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA: Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest. 2005, 115:1210-1220.10.1172/JCI24140

[3] Nakahara T, Dweck MR, Narula N, et al.: Coronary artery calcification: from mechanism to molecular imaging. JACC Cardiovasc Imaging. 2017, 10:582-93. 10.1016/j.jcmg.2017.03.005

[4] Dini CS, Nardi G, Ristalli F, Mattesini A, Hamiti B, and Mario CD: Contemporary approach to heavily calcified coronary lesions. Interv Cardiol Rev. 2019, 14:154-163. 10.15420/icr.2019.19.R1

[5] Barbato E, Shlofmitz E, Milkas A, Shlofmitz R, Azzalini L, Colombo A: State of the art: evolving concepts in the treatment of heavily calcified and undilatable coronary stenoses - from debulking to plaque modification, a 40-year-long journey. EuroIntervention. 2017, 13:696-705. 10.4244/EIJ-D-17-00473

[6] Yeoh J, Hill J: Intracoronary lithotripsy for the treatment of calcified plaque . Interv Cardiol Clin. 2019, 8:411-424. 10.1016/j.iccl.2019.06.004

[7] Reifart N, Vandormael M, Krajcar M, et al.: Randomized comparison of angioplasty of complex coronary lesions at a single center. Excimer Laser, Rotational Atherectomy, and Balloon Angioplasty Comparison (ERBAC) Study. Circulation. 1997, 96:91-98. 10.1161/01.CIR.96.1.91

[8] Waha S, Allali A, Buttner HJ, et al.: Rotational atherectomy before paclitaxel-eluting stent implantation in complex calcified coronary lesions two-year clinical outcome of the randomized ROTAXUS trial. Catheter Cardiovasc Interv. 2016, 87:691-700. 10.1002/ccd.26290

[9] Mauri L, Bonan R, Weiner BH, et al.: Cutting balloon angioplasty for the prevention of restenosis: results of the Cutting Balloon Global Randomized Trial. Am J Cardiol. 2002, 90:1079-1083. 10.1016/S0002-9149(02)02773-X

[10] Brodmann M, Werner M, Brinton TJ, et al.: Safety and performance of lithoplasty for treatment of calcified peripheral artery lesions. J Am Coll Cardiol. 2017, 70:908-910. 10.1016/j.jacc.2017.06.022

[11] Budoff MJ, Young R, Lopez VA, et al.: Progression of coronary calcium and incident coronary heart disease events: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2013, 61:1231-1239.10.1016/j.jacc.2012.12.035

[12] Dini CS, Tomberli B, Mattesini A: Intravascular lithotripsy for calcific coronary and peripheral arterystenoses. EuroIntervention. 2019, 15:714-721. 10.4244/eij-d-18-01056

[13] Giustino G, Mastoris I, Baber U, et al.: Correlates and impact of coronary artery calcifications in women undergoing percutaneous coronary intervention with drug-eluting stents: from the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JACC Cardiovas Interv. 2016, 9:1890-901.10.1016/j.jcin.2016.06.022

[14] Huisman J, van der Heijden LC, Kok MM, et al.: Two-year outcome after treatment of severely calcified lesions with newer-generation drug-eluting stents in acute coronary syndromes: a patient-level pooled analysis from TWENTE and DUTCH PEERS. J Cardiol. 2017, 69:660-665. 10.1016/j.jjcc.2016.06.010

[15] Copeland-Halperin RS, Baber U, Aquino M, et al.: Prevalence, correlates, and impact of coronary calcification on adverse events following PCI with newer-generation DES: findings from a large multiethnic registry. Catheter Cardiovasc Interv. 2018, 91:859-866. 10.1002/ccd.27204

[16] Bourantas CV, Zhang YJ, Garg S, et al.: Prognostic implications of coronary calcification in patients with obstructive coronary artery disease treated by percutaneous coronary intervention: a patient-level poole analysis of 7 contemporary stent trials. Heart. 2014, 100:1158-1164. 10.1136/heartjnl-2013-305180

[17] Brinton TJ, Ali ZA, Hill JM: Feasibility of shockwave coronary intravascular lithotripsy for the treatment of calcified coronary stenoses. Circulation. 2019, 139:834-836. 10.1161/CIRCULATIONAHA.118.036531

[18] Costopoulos C, Naganuma T, Colombo A: Tools and techniques clinical: percutaneous intervention of calcific coronary lesions. EuroIntervention. 2014, 9:1124-1126. 10.4244/EIJV9I9A188

[19] Seth A, Gupta S, Pratap Singh V, Kumar V: Expert opinion: optimising stent deployment in contemporary practice: the role of intracoronary imaging and non-compliant balloons. Interv Cardiol. 2017, 12:81-84.10.15420/icr.2017:12:1

[20] Sadamatsu K, Yoshida K, Yoshidomi Y, et al.: Comparison of pre-dilation with a non-compliant balloon versus a dual wire scoring balloon for coronary stenting. World J Cardiovasc Dis. 2013, 3:395-400.10.4236/wjcd.2013.36061

[21] Jujo K, Saito K, Ishida I, et al.: Intimal disruption affects drug-eluting cobalt-chromium stent expansion: a randomized trial comparing scoring and conventional balloon predilation. Int J Cardiol. 2016, 221:23-31. 10.1016/j.ijcard.2016.07.002

[22] Tumminello G, Cavallino C, Demarchi A, Rametta F: Bail-out unexpanded stent implantation in acute left main dissection treated with intra coronary lithotripsy: a case report. Eur Heart J Case Rep. 2019, 3:1-5. 10.1093/ehjcr/ytz172

[23] Tomey MI, Kini AS, Sharma SK: Current status of rotational atherectomy . JACC: Cardiovasc Interv. 2014, 7:345-353. 10.1016/j.jcin.2013.12.196

[24] Shavadia JS, Vo MN, Bainey KR: Challenges with severe coronary artery calcification in percutaneous coronary intervention: a narrative review of therapeutic options. Can J Cardiol. 2018, 34:1564-1572. 10.1016/j.cjca.2018.07.482

[25] Levine GN, Bates ER, Blankenship JC, et al.: ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv. 2012, 79:453-495. 10.1002/ccd.23438

[26] Cockburn J, Hildick-Smith D, Cotton J, et al.: Contemporary clinical outcomes of patients treated with or without rotational coronary atherectomy - an analysis of the UK central cardiac audit database. Int J Cardiol. 2014, 170:381-387. 10.1016/j.ijcard.2013.11.018 3

[27] Morice MC, Surreyus PW, Sousa JE, Facade J, Hayashi EB, Perini M, Colombo A, Schuler G, Barraging P, Gallium G, Molnar F, Baltic R, for the RAVEL study group. A randomized comparison of sirolimus-eluting stent with a standard stent for coronary revascularization. N Engle J Med 2002; 346: 1773–1780.

[28] Berenguer A, Mianar V, Bordes P, Valencia J, Gomez S, Lozano T. Incidence and predictors of restenosis after sirolimus eluting stent implantation in high risk patients. Am Heart J 2005; 150: 536–542.

[29] Moussa I, Mario CD, Moses J, Reimers B, Francesco LD, Martini G, Tobis J, Colombo A. Coronary stenting after rotational atherectomy in calcified and complex lesions: Angiographic and clinical follow-up results. Circulation 1997; 96: 128–136.

[30] Rathore S, Terashima M, Katoh M, et al. Predictors of angiographic restenosis after drug eluting stents in the coronary arteries: Contemporary practice in real world patients. Eurointervent 2009; 349–354.

[31] Brogan WC III, Popma JJ, Pichard AD, et al. Rotational atherectomy after unsuccessful coronary balloon angioplasty. Am J Cardiol 1993; 71: 794–798.

[32] Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'shaughnessy C, Caputo RP, Kereikas DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE, for the SIRIUS investigators. Sirolimus eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315–1323.

[33] Migliorini A, Shehu M, Carrabba N, Giurlani L, Valenti R, Buonamici P, Dovellini EV, Parodi G, Antoniucci D. Predictors of outcome after sirolimus eluting stent implantation for complex in stent restenosis. Am J Card 2005; 96: 1110–1112.

[34] Mintz G, Dussaillant G, Wong C, Pichard A, Satler L, Bucher T, Leon M. Rotational atherectomy followed by adjunct stents: The preferred therapy for calcified lesions in large vessels? Circulation 1995; 92 (Suppl I): I-329.

[35] Clavijo LC, Steinberg DH, Torguson, et al. Sirolimus eluting stents and calcified coronary lesions: Clinical outcomes of patients treated with and without rotational atherectomy. Cathet Cardiovasc Interv 2006; 68: 873–878.

[36] Harani, A., VijayaRatnam, J., Dipankar, B., Kumar, D. S., Lalitha, M. B., & Kumar, S. P. N. (2018). Molecular interaction studies of phosphatidylcholine as drug delivery substrate for asenapine maleate. Current Science, 115(3), 499–504.

[37] Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, Dudek D, Fort S, Schiele F, Zmudka K, Guagliumi G, Russell ME, for the TAXUS II study group. Randomized study to assess the effectiveness of slow and moderate release polymer based paclitaxel eluting stents for coronary artery lesions. Circulation 2003; 108: 788–794.

[38] Alfonso F, Macaya C, Goicolea J, Hernadez R, Segovia J, Zamorano J, Banvelos C, Zarco P. Determinants of coronary compliance in patients with coronary artery disease: An intravascular ultrasound study. J Am Coll Cardiol 1994; 23: 879–884.

[39] Warth D, Leon M, O'Neill W, Zacca N, Polissar N, Buchbinder M. Rotational atherectomy multicenter registry: Acute results, complications and 6-month angiographic follow-up in 709 patients. J Am Coll Cardiol 1994; 24: 641–648.

[40] Schluter M, Cosgrave J, Tubler T, et al. Rotational atherectomy to enable sirolimus eluting stent implantation in calcified, nondilatable de novo coronary artery lesions: Mid term clinical and angiographic outcomes. Vasc Dis Manag 2007; 4: 63–69.

[41] Rosenblum J, Stretzer SH, Shaw RE, et al. Rotational ablation of balloon angioplasty failures. J Invasive Cardiol 1992; 4: 312–318.

[42] Halkin A, Stone GW. Polymer based paclitaxel eluting stents in percutaneous coronary intervention: A review of the TAXUS trials. J Interv Cardiol 2004; 17: 271–282.

[43] Fitzgerald P, Ports T, Yock P. Contribution of localized calcium deposits to dissection after angioplasty: An observational study using intravascular ultrasound. Circulation 1992; 86: 64–70.

[44] Ellis S, Popma J, Buchbinder M, Franco I, Leon M, Kent K, Pichard A, Satler L, Topol E, Whitlow P. Relation of clinical presentation, stenosis morphology, and operator technique to the procedural results of rotational atherectomy-facilitated angioplasty. Circulation 1994; 89: 882–892.

[45] Moussa I, Ellis SG, Jones M, et al. Impact of coronary culprit lesion calcium in patients undergoing paclitaxel eluting stent implantation (a TAXUS-IV substudy). Am J Cardiol 2005; 96: 1242–1247.

[46] Sharma SK. Rotational atherectomy prior to coronary stenting prevents side branch occlusion (abstract). J Am Coll Cardiol 1997; 29: 498A.

[47] Lemos PA, Hoye A, Goedhart, Aramptzais CA, Saia F, et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus eluting stents in complex patients: An evaluation from the Rapamysin-Eluting Stent evaluated at Rotterdam Cardiology Hospital (RESEARCH) study. Circulation 2004; 109: 1366–1370.

[48] Fitzgerald P, for the STRUT Registry Investigators. Lesion composition impacts size and symmetry of stent expansion: Initial report from the strut registry. J Am Coll Cardiol 1995; 49A: 902.

[49] Henson K, Popma J, Leon M, Kent K, Satler L, Mintz G, Keller M, Deible R, Pichard A. Comparison of results of rotational coronary atherectomy in three age groups(<70, 70–79, and >80 years). Am J Cardiol 1993; 71: 862–864.

[50] Kuntz RE, Safian RD, Carrozza JP, et al. The importance of acute luminal diameter in determining restenosis after coronary atherectomy or stenting. Circulation 1992; 86: 1827–1835.

[51] Zahn R, Hamm CW, Schneider S, Zeymer U, Nienaber CA, Richardt G, Kelm M, Levenson B, Bonzel T, Tebbe U, Sabin G, Senges J, for the German Cypher Registry. Incidence and predictors of target vessel revascularization and clinical event rates of the sirolimus eluting coronary stent (Results from the Prospective Multicenter German Cypher Stent Registry). Am J Cardiol 2005; 95: 1302–1308.

[52] Thummala UK, Vallabhareddy PS, Sarella PN. Enhancing Oral Absorption of Orlistat through Gastroretentive Mucoadhesive Pellets: Formulation and Evaluation. Journal of Clinical and Pharmaceutical Research. 2023 Apr 30:9-17.

[53] Safian R, Niazi K, Strazeleski M, Lichtenberg A, May M, Juran N, Freed M, Ramos R, Gangadharan V, Grines C, O'Neil W. Detailed angiographic analysis of high-speed mechanical rotational atherectomy in human coronary arteries. Circulation 1993; 88: 961–968.

[54] Prakash Nathaniel Kumar Sarella, Pavan Kumar Thammana. Potential applications of Folate-conjugated Chitosan Nanoparticles for Targeted delivery of Anticancer drugs. Research Journal of Pharmaceutical Dosage Forms and Technology2023; 15(4):281-8. doi: 10.52711/0975-4377.2023.00045.

[55] Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, O'shaughnessy CD, DeMario S, Hall P, Popma JJ, Koglin J, Russell ME. Comparison of polymer based paclitaxel eluting stent with a bare metal stent in patients with complex coronary artery disease: A randomized controlled trial. JAMA 2005; 294: 1215–1223.

[56] Kovach JA, Mintz GS, Pichard AD, Kent KM, Popma JJ, Satler LF, Leon MB. Sequential intravascular ultrasound characterization of the mechanisms of rotational atherectomy and adjunct balloon angioplasty. J Am Coll Cardiol 1993; 22: 1024–1032.

[57] Khattab AA, Otto A, Hochadel M, Toelg R, Geist V, Richardt G. Drug eluting stents versus bare metal stents following rotational atherectomy for heavily calcified coronary lesions: Late angiographic and clinical follow-up results. J Intervn Cardiol 2007; 20: 100–106.

[58] Moussa I, Di Mario C, Reimers B, Akiyama T, Tobis J, Colombo A. Subacute stent thrombosis in the era of intravascular ultrasound guided coronary stenting without anticoagulation: Frequency, predictors and clinical outcome. J Am Coll Cardiol 1997; 29: 6–12.

[59] Asogwa PO, Sarella PN. Observational Studies of Prescription Pattern and Use of Antibiotics in Selected Rural Areas. Int J Pharm Sci and Medicine. 2023;8:21-30.

[60] Stertzer S, Pomerantsez E, Shaw R, Boucher R, Millhouse F, Zipkin R, Hidalgo B, Murphy M, Hansell H, Myler R. Comparative study of the angiographic morphology of coronary artery lesions treated with PTCA, directional atherectomy, or high speed rotational ablation. Cathet Cardiovasc Diagn 1994; 33: 1–9.

[61] Kiesz RS, Rozek MM, Ebersole DG, et al. Novel approach to rotational atherectomy results in low restenosis rates in long, calcified lesions: Long term results of San Antonio Rotablator Study (SARS). Cathet Cardiovasc Interv 1999; 48: 48–53.

[62] Henneke KH, Regar E, Konig A, et al. Impact of target lesion calcification on coronary stent expansion after rotational atherectomy. Am Heart J 1999; 137: 93–99.

[63] Windecker S, Remondino A, Ebreli FR, Juni P, Raber L, Wenaweser P, Togni M, Billinger M, Tuller D, Seiler C, Roffi M, Corti R, Sutsch G, Maier W, Luscher T, Hess OM, Egger M, Meir B. Sirolimus-eluting and Paclitaxel eluting stents for coronary revascularization. N Engl J Med 2005; 353: 653–662.

[64] Stertzer S, Rosenblum J, Shaw R, Sugeng I, Hidalgo B, Ryan C, Hansell H, Murphy M, Myler R. Coronary rotational ablation: Initial experience in 302 procedures. J Am Coll Cardiol 1993; 21: 287–295.

[65] Tamekiyo H, Hayashi Y, Toyofuku M, et al. Clinical outcomes of sirolimus eluting stenting after rotational atherectomy. Circ J 2009; 73: 2042–2049.

Author's short biography

Suraj Agrahari

With a background in pharmacy research, my research works seamlessly integrates cutting-edge discoveries and also have some more interest in some new things in pharmaceutical research.

Mr.Shubham Garg

Mr.Shubham Garg is an assistant professor and he have more interest in pharmaceutical research.

Aamir Hussain war

UG Scholar studying BPharmacy in RIMT university, passionate about cellular and molecular pharmacology

Abhishek Kumar

UG Scholar studying BPharmacy in RIMT university. Aspire to become a clinical pharmacist and take part in clinical trials involving drug design and research

Mussadiq Hussain Tantray

UG Scholar studying BPharmacy in RIMT university, interested in latest research in method developments and validation of newly FDA approved drugs

Rajat Koundal

Mr. Rajat Koundal is an Associate Professor in RIMT university. He is interested in pharmaceutical technology and modern analytical tools

Hurmandeep Kaur

As a pharmacist-turned-researcher, Im interested in pharmaceutical research, blending scientific accuracy with recent advances